Restoring the Balance in the Brain

We develop the next generation of CNS therapeutics

Gabather is a pharmaceutical company developing the next generation of therapeutics for neuropsychiatric disorders, based on the ability of our proprietary drug candidates to restore the balance in the brain and enhance cognitive function.

About Us

Drug candidates

Drug candidates

Our most advanced drug candidate, GT-002, has completed phase I clinical trials. GT-002 has been shown to have excellent pharmacokinetics, as well as being safe and well-tolerated.

Read more

 Vision

Vision

Our vision is to bring novel transformative medicine to the patient to treat psychiatric disorders in a fast and effective way.

Read more

Focus areas

Focus areas

Gabather has four focus areas with huge unmet medical needs: anti-psychotics, anti-depressants and anxiolytics, analgesics, as well as cognition-enhancing treatments, including Alzheimer’s disease. 

Read more

Approach

Approach

We believe our innovative drug development approach offers unique opportunities to develop potentially transformative medicines that will achieve our main goal, providing improved treatments of mental diseases in an effective way.

Read more

Background

Background

We have more than 10 years of research at both Lund University and the Research Institute of Biological Psychiatry in Roskilde as the basis for our development projects.

Read more

Press Releases

Here you will find the latest press releases from Gabather. You can find more in our Investors section. Certain news are only published in Swedish.

more press releases